Erythroid dysplasia is the pathologic hallmark of myelodysplastic syndromes (MDS). To develop a quantitative flowcytometry approach to its evaluation, we analyzed the expression of CD71, CD105, cytosolic H-ferritin (HF), cytosolic L-ferritin (LF) and mitochondrial ferritin (MtF) in erythroblasts from 104 MDS patients, 69 pathologic control patients and 19 healthy subjects. Six-parameter, 4-color flow cytometry was employed, and data were expressed as mean fluorescence intensity. Compared with pathologic and healthy controls, MDS patients had higher expression of HF (Po0.001) and CD105 (Po0.001), and lower expression of CD71 (Po0.001). MtF was specifically detected in MDS with ringed sideroblasts, and there was a close relationship between its expression and Prussian blue staining (r ¼ 0.89, Po0.001). In vitro cultures of myelodysplastic hematopoietic progenitors showed that both HF and MtF were expressed at a very early stage of erythroid differentiation, and that MtF expression is specifically related to mitochondrial iron loading. A classification function based on expression levels of HF, CD71 and CD105 allowed us to correctly classify 495% of MDS patients. This flow-cytometry approach provides an accurate quantitative evaluation of erythroid dysplasia and allows a reliable diagnosis of sideroblastic anemia, and may therefore be a useful tool in the work-up of patients with MDS.
Introduction
The current diagnostic approach to myelodysplastic syndrome (MDS) includes peripheral blood and bone marrow (BM) morphology (to evaluate abnormalities of peripheral blood cells and hematopoietic precursors), BM biopsy (to assess marrow cellularity and topography), and cytogenetics (to identify nonrandom chromosomal abnormalities). 1 The pathologic hallmark of MDS is marrow dysplasia, which represents the basis of the World Health Organization (WHO) classification of these disorders. 2, 3 The combination of overt marrow dysplasia and clonal cytogenetic abnormality allows a conclusive diagnosis of MDS, but this is found in only a portion of patients. 4 In many instances, cytogenetics is not informative, and the diagnosis of MDS is based entirely and exclusively on morphological criteria. Moreover, the diagnostic process may be particularly challenging in the one-fifth of MDS patients who have hypoplastic BM, similar to the picture in aplastic anemia. 5 Flow-cytometry immunophenotyping is a reliable method for quantitative and qualitative evaluation of hematopoietic cells. Its use in the analysis of myelodysplastic marrows initially showed abnormal expression of various surface antigens. 6 Several studies have later evaluated the clinical utility of this approach in MDS patients [7] [8] [9] [10] and we have recently developed a flow-cytometry approach for the evaluation of marrow dysplasia using discriminant analysis to generate erythroid and myeloid classification functions that was proven to be sensitive in a high proportion of cases with indeterminate morphology, as well as repeatable and reproducible in a intra-laboratory setting. 11 Evaluation of erythroid dysplasia represents a challenge in the immunophenotypic analysis of myelodysplastic marrows, mainly because of the limited availability of specific antibodies. To overcome this limitation, we developed a flow-cytometric approach largely based on the evaluation of proteins of erythroid iron metabolism. The rationale for this was previous findings from our laboratory indicating abnormal cytosolic and mitochondrial ferritin (MtF) expression in erythroid cells from MDS patients. 12, 13 In the present study, we employed antibodies against cytosolic ferritin subunits (H-ferritin (HF) and L-ferritin (LF)), MtF, and transferrin receptor (CD71). We also employed a monoclonal antibody against CD105 (endoglin), an accessory receptor for members of the transforming growth factor beta superfamily, which was previously found to be specifically expressed on proerythroblasts.
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Materials and methods
Patients and controls
This prospective, single-institution study enrolled 104 consecutive MDS patients 69 pathologic control patients as well as 19 BM healthy donors followed at the Division of Hematology, IRCCS Policlinico San Matteo and University of Pavia Medical School (Table 1) . The procedures followed were in accordance with the ethical standards of the institutional committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.
Cytological diagnosis of MDS was made according to the WHO classification. 2 Morphological analysis of marrow specimens was performed by two independent blinded cytologists (ET, RI). The degree of erythroid dysplasia was defined according to the following morphological scoring system: 0 (absence of dysplasia, 0-2% of abnormal cells), 1 (mild dysplasia, 3-9% of abnormal cells), 2 (moderate dysplasia, 10-29% of abnormal cells) and 3 (severe dysplasia, 30% or more abnormal cells).
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Cytogenetic analysis was performed at diagnosis, using standard G-banding with trypsin-Giemsa staining as recently described. 16 The International Prognostic Scoring System (IPSS) was employed to define prognosis according to Greenberg et 
Flow-cytometry studies on bone marrow erythroid cells
Flow-cytometry studies were performed on heparinized BM aspirate specimens. Samples were collected and stained within 3 h using a whole blood lysis technique (NH 4 Cl) according to standard procedures previously described. 18, 19 For intracellular antigens staining cells were fixed (Fixation Medium -FIX& PERM, Caltag Laboratories Burlingame, CA, USA) and resuspended in 0.5% (w/v) saponin (Sigma, St Louis, MO, USA) for 30 min for permeabilization.
Multiparametric 4-color flow-cytometry acquisition was performed with a Coulter Epix XL flow cytometer (Beckman Coulter, Milan, Italy). Daily instrument quality control was performed to ensure identical operation from day to day. 19 At least 100 000 events were acquired for each sample in linear mode for side scatter (SSC) and in log mode for fluorescent signals. Data (collected in list mode) were analyzed using the EXPO32 ADC software (Beckman Coulter).
The monoclonal antibody panel employed following the manufacturer's instructions was as follows: fluorescein isothiocyanate (FITC)-conjugated anti-CD71 and anti-glycophorin A (GlyA); phycoerythrin (PE)-conjugated anti-CD71, anti-CD105 and anti-GlyA; PE-Texas Red (ECD)-conjugated anti-CD45. All antibodies were purchased by Becton Dickinson (San Jose, CA, USA) and Coulter-Instrumentation Laboratory (Milan, Italy). In addition, we have utilized a purified monoclonal mouse antibody anti-HF (rH02) and LF (LF03) subunits as previously described, 12 and a purified polyclonal antibody raised in mice against and specific for MtF. 13 FITC-conjugated goat anti-mouse IgG (Becton Dickinson) was employed in indirect immunofluorescence staining. Finally, Laser Dye Styryl (LDS751, Molecular Probes, Leiden, The Netherlands) was used for nuclear cell identification. Isotype-matched negative controls or non-immune mouse serum were used in all assays. 11 The indirect and intracellular staining was performed as first step followed by membrane staining.
Erythroblasts were gated using a combination of LDS751/ CD45/GlyA. Gating strategy to identify erythroid precursors was based on nuclear staining to exclude cellular debris: erythroblasts were defined in LDS751 þ gate as GlyA þ /CD45lowÀ/ SSClow cells. 11 ( Figure 1 ). Immunophenotypic data were expressed as mean fluorescence intensity (MFI) ratio as described by Maynadié et al. 8 The MFI ratio was calculated as the ratio between the MFI of the specific marker tested to the MFI of the negative control included in the assay. Samples from three MDS patients were evaluated to test the intra-laboratory repeatability and reproducibility of specimen preparation, gating strategy, acquisition and analysis. Briefly, for a single sample, aliquots were prepared in replicate by four independent investigators, who then analyzed, in a blind manner, each specimen three times.
Flow-cytometry analysis of cultured erythroid cells
Mononuclear BM cells were enriched for CD34 þ cells by two cycles of positive selection using the MiniMacs system (Miltenyi Biotech, Bologna, Italy) following the manufacturer's instructions. Selected CD34 þ cells were resuspended at the final concentration of 0.5-1 Â 10 5 /ml in Iscove medium (Sigma, St Louis, MO, USA) supplemented with 15% BIT9500 serum substitute (Stem Cell Technologies, Tebu-Bio, Milan, Italy). Cells were incubated in 5% CO 2 in air, at 371C for 14 days. A cytokine mixture containing 10 ng/ml recombinant human interleukin 3 (rh-IL-3; PeproTech House, Tebu-Bio, Milan, Italy), 10 ng/ml rh-IL-6 (PeproTech House), 25 ng/ml rh-stem cell factor (rh-SCF; PeproTech House) was added on day 0 and subsequently every 3 days. Recombinant human erythropoietin (rh-Epo, 2 IU/ml; Janssen Cilag, Milan, Italy) was added to the culture at days 7, 9 and 11. 20 In order to evaluate erythroid maturation, flow-cytometry analysis of cultured cells were performed at days 0, 4, 7 and 14. Cells were stained using FITC-conjugated anti-CD71, PEconjugated anti-CD71 and anti-GlyA, PE-Texas Red (ECD)-conjugated anti-CD34, PC5-conjugated anti-CD45 (Becton Dickinson and Coulter Instrumentation Laboratory). Finally, HF, LF and MtF expression was evaluated on CD71 þ cells using specific antibodies as described above.
Statistical analysis
Numerical variables are summarized by their median and quartiles or ranges. Categorical variables are described by counts and relative frequencies. Analyses of variance comparing means between groups were performed to test each numerical parameter for differences between MDS patients, pathologic and healthy controls. A logarithmic transformation was performed to normalize the distribution of the variables. Post hoc comparisons were carried out using Scheffe's test. Association between ordinal and continuous variables was tested by linear regression A repeated measure analysis of variance was carried out on data obtained from three MDS samples evaluated by four blinded independent investigators, who analyzed each sample three times, in order to estimate the between-investigator and within-investigator (or trial-to-trial) coefficients of variation (CV). All analyses were performed using Statistica 6.0 software (Statsoft Inc., Tulsa, OK, USA) and Microsoft s Excel 2000 (Microsoft Inc., Redmond, WA, USA).
Results
Flow-cytometry analysis of bone marrow erythroid cells
Bone marrow erythroblasts were gated as LDS751 þ /CD45À/ GlyA þ cells. Analysis of immunophenotypic expression of CD71, HF, LF, MtF and CD105 was carried out comparing MDS patients with pathologic and healthy controls. A comparison between MDS subgroups was also performed, considering patients with or without ringed sideroblasts (RS) and patients without or with excess blasts (o5% versus X5%). Finally, in order to test the influence of cytogenetics on the immunophenotypic expression of the tested antigens, patients were grouped adopting IPSS criteria ('good-risk' patients with normal karyotype, del(20q) or del(5q), versus 'intermediate-or high-risk' patients with other isolated abnormalities or with more than one cytogenetic defect) adjusted for BM percentage of blasts.
Higher expression of HF was observed in erythroblasts from MDS patients compared with those from pathologic and healthy controls (Po0.001) ( Table 2) . Among MDS subgroups, subjects with intermediate-or high-risk cytogenetics presented increased levels of HF with respect to good-risk patients (P ¼ 0.03). Significant correlations were found between HF expression and serum ferritin in both controls (r ¼ 0.59, Po0.001) and MDS patients (r ¼ 0.31, P ¼ 0.01), and between HF expression and degree of erythroid dysplasia assessed by morphology (r ¼ 0.62, Po0.001).
Higher expression of LF was observed in erythroblasts from MDS with respect to those from pathologic and healthy controls (Po0.001) ( Table 2) , without significant differences among MDS subgroups. Positive correlations between LF level and serum ferritin were found both in controls (r ¼ 0.39, P ¼ 0.002) and in MDS patients (r ¼ 0.36, P ¼ 0.003). In myelodysplastic erythroblasts the increase in HF was comparatively higher than that of LF (Po0.001). Accordingly, the ratio of HF to LF expression (H/L ratio) was higher in MDS patients than in pathologic and healthy controls (Po0.001) despite a large variability in these latter. In order to assess the effect of diagnosis on HF level also accounting for body iron status and filtering out the potential effect of iron overload due to transfusions, we carried out a multivariate analysis adjusted for serum ferritin and LF. A significantly increased level of HF expression was noticed in MDS compared to controls (Po0.001). Myelodysplastic syndrome patients presented lower levels of transferrin receptor (CD71) in comparison with pathologic and healthy controls (Po0.001) ( Table 2) , which appear significantly decreased in patients with intermediate-or high-risk cytogenetics (P ¼ 0.037) with respect to good-risk patients. Among control groups, a higher CD71 expression was found in healthy subjects with respect to pathologic control patients (P ¼ 0.001). A significant negative correlation was found between degree of morphological erythroid dysplasia and flow-cytometric expression of CD71 (r ¼ À0.44, Po0.001). The level of CD71 inversely correlated with the expression of HF (r ¼ À0.53, Po0.001), while only a mild negative correlation was noticed between CD71 and LF expression (r ¼ À0.21, P ¼ 0.02).
Myelodysplastic syndrome patients showed higher CD105 levels than pathologic and healthy controls (Po0.001) ( Table 2) . A significant difference was found between MDS with and without RS (P ¼ 0.02), the former ones having higher CD105 expression. A significant correlation was noticed between CD105 expression and degree of erythroid dysplasia as assessed by morphology (r ¼ 0.47, Po0.001).
As far as MtF expression is concerned, a strong correlation was found between flow-cytometric MtF detection and Perls staining (r ¼ 0.89, Po0.001). Within MDS patients, significantly higher MtF levels were found in individuals with than in those without RS (Po0.001) ( Table 2 ). No significant relationship was observed between MtF level and either HF or LF expression, while a significantly positive correlation was found between MtF and CD71 in erythroid cells (r ¼ 0.45, P ¼ 0.006). The analysis of the erythroid compartment in MDS patients with RS showed that MtF-positive cells presented significantly higher CD71 levels in comparison with MtF-negative cells (P ¼ 0.013).
Flow-cytometry analysis of erythroid cultures
Erythroid progenitor cells cultures were performed in 16 MDS patients (five refractory anemia (RA), four refractory cytopenia with multilineage dysplasia (RCMD), five refractory anemia with ringed sideroblasts (RARS) and two 5q-syndrome) and in five controls (three pathologic and two healthy controls). The purity of CD34 þ isolated cells was more than 95% in all cases.
At day 4, a median of 38.4% (range 32.2-45.4) of cells were CD34 þ /CD71À, 24.5% (18.4-30) were CD34 þ /CD71 þ , while 13.7% (9.5-20.1) were CD34À/CD71 þ . At day 7, 13.5% of cells (10.4-22.5) were CD34 þ /CD71À, 22.2% (15.6-31.6) were CD34 þ /CD71 þ , 29.2% (24.1-34.4) were CD34À/CD71 þ and 8.75% (6.8-9.4) were GlyA þ . At day 14, the median percentage of CD71 cells was 84.1% (68.1-92.2) and 62.6% (59.9-76.5) were GlyA þ .
Freshly isolated CD34 þ cells stained negative for CD71 and MtF, and expressed low levels of HF and LF (Figure 2a-c) . At day 4, increased HF levels were observed in CD71 þ cells of MDS patients as compared with controls (Pp0.001). This significant difference was maintained at days 7 (Pp0.001) and 14 (Pp0.001) (Figure 2a) .
No significant difference was present between MDS patients and controls with respect to LF expression during erythroid differentiation (Figure 2b ). By contrast, significant difference between MDS and control group was observed in CD71 levels of GlyA þ cells at day 14, MDS patients showing a downregulation of transferrin receptor (P ¼ 0.002). No difference in HF, LF and CD71 expression was noticed among RA, RCMD and 5q-syndrome subgroups.
Cultured cells from control subjects and MDS patients without RS, stained negative for MtF at any times of differentiation. On the contrary, a peculiar pattern was observed in MDS patients with RS: there was a significant increase in MtF levels at day 4 (Po0.001), and this difference was maintained at day 7 (Po0.001) and at day 14 (Po0.001) (Figure 2c ).
Discriminant analysis of erythroid dysplasia
This part of the study involved two cohorts of patients and controls: (a) a 'learning cohort,' whose investigations were aimed at defining discriminant immunophenotypic markers; (b) a 'testing cohort' on which we prospectively examined whether our discriminant markers were able to reproduce what we had found in the learning cohort.
The 'learning cohort' included 36 MDS patients (11 RA, two RCMD, seven RARS, four RCMD-RS, one MDS with del(5q), four RAEB-1 and seven RAEB-2), 14 pathologic controls (two hypoproliferative anemia, two iron deficiency anemia, five anemia of chronic disease, one megaloblastic anemia, one hemolytic anemia and three iatrogenic aplasia) as well as nine healthy subjects.
With the aim of distinguishing MDS patients from controls we performed a discriminant analysis based on flow-cytometry estimates that were found to be related to erythroid dysplasia. A definitive classification function was obtained as a linear combination of the following immunophenotypic variables (log transformed): HF, CD71 and CD105. In order to classify a subject, the function must be evaluated using the patient's values of the selected parameters: the patient will be classified as having erythroid dysplasia if the obtained value is greater than zero or as not having erythroid dysplasia if the value is lower than zero. Table 3 shows the erythroid classification function. This function was integrated with the immunophenotypic evaluation of MtF in order to differentiate MDS patients with All the variables were log transformed before the analysis of variance to normalize the distribution.
Erythroid dysplasia in myelodysplastic syndromes MGD Porta et al or without RS (the lowest MFI value of MtF observed in patients with RS (3.3) was chosen as threshold). Thirty-five of the 36 MDS patients were correctly classified (97.2% sensitivity). No false-positive results were noticed among pathologic and healthy controls (100% specificity). Within the MDS group, a correct classification of patients with RS was obtained in 17/17 cases (100% sensitivity), with one false-positive case (94.7% specificity). A significant positive correlation was observed between the numerical value of the erythroid classification function and the degree of the erythroid marrow dysplasia assessed by morphology (r ¼ 0.53, Po0.001).
The obtained classification function was then prospectively validated on a series of 123 consecutive, unselected patients referred to our institution for anemia as well as in 10 healthy donors. A morphological diagnosis of erythroid dysplasia was carried out in 53 cases (11 RA, nine RARS, six RCMD, six RCMD-RS, one MDS with del(5q), five RAEB-1, 15 RAEB-2). In 15 patients no definitive evidence of morphological erythroid dysplasia was found at the time of diagnosis; in these cases the diagnosis of MDS (one RA, 10 RCMD, two RAEB-1, one RAEB-2, one MDS unclassified) was formulated basing on the presence of myeloid or megakaryocytic dysplasia, as well as of cytogenetic abnormalities and confirmed by flow-up investigations. The remaining 55 patients had iatrogenic aplasia (four cases), hypoproliferative anemia (eight cases), iron deficiency anemia (15 cases), anemia of chronic disease (10 cases), megaloblastic anemia (four cases), hemolytic anemia (13 cases) and congenital sideroblastic anemia (one case).
A correct diagnosis was obtained in 52 out of 53 MDS cases showing erythroid dysplasia (98.1% sensitivity). The falsenegative case was a patient with a RCMD and mild anemia (hemoglobin value 11.5 g/dl). Among MDS subgroups, increased values of the erythroid classification function were noticed in patients with intermediate-or high-risk cytogenetics in comparison with good-risk cytogenetics patients (P ¼ 0.044). Among 65 subjects without erythroid dysplasia (10 healthy subjects, 55 anemic controls), a patient with hemolytic anemia was incorrectly classified as MDS (98.5% specificity). In MDS group, a corrected classification of MDS with RS was obtained in 21/21 cases (100% sensitivity and specificity).
Finally, we tested the flow-cytometric discriminant function in a series of 15 MDS patients without a conclusive morphological evidence of erythroid dysplasia. Among these patients, flowcytometric analysis demonstrated the presence of erythroid dysplasia in 9/15 cases (60%).
Samples from three MDS patients were evaluated in order to test the intra-laboratory repeatability and reproducibility of specimen preparation, gating strategy to identify immature erythroid cells, acquisition and analysis of the cytometric parameters included in the discriminant function. A repeated measure analysis of variance showed that the between-and the within investigator did not affect significantly the results. Between-and within-investigator coefficient of variation were calculated for the parameters of interest (Table 4) .
Discussion
Flow-cytometry immunophenotyping has been employed only seldom in the evaluation of erythroid dysplasia due to the lack of available specific markers. 7, 8 In our previous study, dissyncronous expression of transferrin receptor (CD71) versus GlyA on nucleated red cells precursors was the only consistent erythroid abnormality. 11 To expand the potential of immunophenotyping we have designed a flow-cytometry approach largely based on the evaluation of proteins of iron metabolism, which are clearly important in erythroid cells. 12 Ferritin plays a critical role in regulating intracellular iron homeostasis by storing iron inside its multimeric shell, whereas transferrin receptor (CD71) is indispensable for cellular iron uptake. 21, 22 Pham et al. 23 have recently shown that HF is an essential mediator of the antioxidant and protective activities of NF-kB transcription factors, which antagonize apoptosis induced by tumor necrosis factor. In the present study, we found significantly higher HF levels in MDS patients. The results of a multivariate analysis adjusted for body iron status showed a significant effect of diagnosis on HF level, suggesting the involvement of mechanisms other than intracellular iron in the abnormal regulation of HF expression in myelodysplastic erythroid cells. Interestingly, NF-kB activity has been found to be increased in myelodysplastic BM cells, 24 and this may result in increased transcription of HF. 23 Thus, HF might act as an antiapoptotic agent in myelodysplastic erythroblasts.
Decreased levels of transferrin receptor (CD71) were found in MDS patients, as previously reported. 7, 11 Since transferrin receptor levels are mainly regulated at the translational level by iron regulatory proteins, 21 this confirm that myelodysplastic erythroid cells have an 'iron-loaded' phenotype, characterized by increased ferritin contents and reduced transferrin receptor expression. Thus, the combination of decreased CD71 and increased HF expression may be considered as a marker of dysplasia.
We confirmed by flow cytometry that MtF expression is closely related to the presence of ringed sideroblasts in the BM. 13 Since the distinction between ferritin and ringed sideroblasts after Prussian blue staining is often difficult, flowcytometry demonstration of MtF might in the future become the standard approach to diagnosis of sideroblastic anemia. Interestingly, MtF-positive cells presented increased levels of CD71 than MtF-negative erythroid cells. This observation may indicate a link between MtF and transferrin receptor expression: might be related to the cytosolic iron deprivation induced by the presence of MtF. 25, 26 In an erythroid culture model we found that aberrant MtF expression, as well as induction of HF, occur at very early stage of differentiation, confirming a strong relationship with the myelodysplastic phenotype. 20 A distinctive sign of ineffective erythropoiesis is a high proportion of immature erythroblasts. In this study, we found an increased expression of CD105, a marker expressed on proerythroblasts, 14, 15 in MDS with respect to controls. Moreover, CD105 level was significantly associated with the degree of erythroid dysplasia assessed by morphology.
The evaluation of HF, CD71, CD105 and MtF was combined in a flow-cytometric approach that was tested in the diagnostic work-up of MDS patients. We defined a classification function that proved useful in distinguishing MDS from other conditions. This approach allowed us to correctly classify more than 95% of MDS and pathologic controls. Moreover, it was proven to be informative in a high proportion of cases with a non-conclusive morphological analysis. This seems to suggest that flowcytometric analysis is more sensitive than morphology and less influenced by sample quality. Finally, the quantitative evaluation provided by the discriminant function reflected the severity of marrow erythroid dysplasia and was more prominent in patients with unfavorable cytogenetics, which is the most important predictor of the severity of the disease. 3 Erythroid dysplasia is found in almost all patients with MDS and is the only morphological abnormality in those with refractory anemia, that is, the pure erythroid disorders of the WHO classification.
2 However, as underlined by Vardiman, 27 inter-observer reproducibility for recognition of dysplasia is often inadequate, particularly in low-grade MDS. In one study, 28 inter-observer agreement was good for recognition of ringed sideroblasts but strikingly poor for erythroid dysplasia.
Flow cytometry can provide better reproducibility than morphology. Our analysis was based on the quantification of MFI, which was recently applied and validated in a prospective multicenter study of EGIL group in MDS patients. 8 Moreover, data obtained from a repeated measure analysis showed that this approach is repeatable and reproducible, at least in an intralaboratory setting.
In conclusion, an accurate flow-cytometry evaluation of marrow erythroid dysplasia was achieved in this study with a panel of six antibodies, including CD45, GlyA, CD71, CD105, HF and MtF. This immunophenotypic approach proved to be accurate and reproducible, and therefore potentially useful tool in the work-up of MDS. The repeatability and reproducibility of erythroblast gating strategy was evaluated as the percentage of cells.
